Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study-Reference-Cited by-同舟云学术

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study

Published:2020-03-24 Issue:15 Volume:26 Page:3918-3927
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Byrd John C.,Furman Richard R.,Coutre Steven E.,Flinn Ian W.,Burger Jan A.,Blum Kristie,Sharman Jeff P.,Wierda William,Zhao Weiqiang,Heerema Nyla A.,Luan Ying,Liu Emily A.,Dean James P.,O'Brien Susan

Funder

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 135 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study;The Lancet Haematology;2024-09

2. Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments;Advances in Rheumatology;2024-08-21

3. BTK inhibitors: moving the needle on the treatment of chronic lymphocytic leukemia;Expert Review of Hematology;2024-08-21

4. New pharmacodynamic parameters linked with ibrutinib responses in chronic lymphocytic leukemia: Prospective study in real-world patients and mathematical modeling;PLOS Medicine;2024-07-22

5. Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-07-10